For Not(e)able - pelareorep is an IMMUNE PLATFORM MOLECULEJohnson & Johnson's teclistamab, a BCMAxCD3 bispecific antibody, was granted EU approval to treat relapsed and refractory multiple myeloma after at least three prior therapies, including chemotherapy, IMiDs, proteasome and CD38 inhibitors.
Teclistamab works by redirecting CD3-positive T cells to myeloma cells that express BCMA to kill off the cancer cells.
The use of teclistamab follows prior treatment with CAR-T therapy and/or an antibody drug conjugate (ADC). The multiple myeloma market is already an over-crowded market with multiple pharma companies seeking an effective combination of drugs for the treatment of this blood (liquid) cancer.
Meanwhile ONCY has shown postive results in the development of their (pelareorep x CD3) bispecific antibody combinaiton in breast and pancreatic cancer tumor models. CD3-bispecific antibodies are designed to facilitate cancer killing by simultanelusly engaging both T-cell and tumor tissue, while clinical studies have already demonstrated pelareorep's ability to recruit T-cells to solid tumors. This provides a strong rationale for targeting the use of pelareorep in combination with CAR-T therapy in solid tumors, which is a significantly larger market than is multiple myeloma.
The multi-targeted approach that ONCY has taken in demonstrating pelareorep multifaceted MOA in combination with multiple I/O agents has enabled ONCY to address multiple cancers (both liquid and solid tumor) in a growing cancer market. By doing so, ONCY has demonstrated that pelareorep is an IMMUNE PLATFORM MOLECULE, whose synergistic potential extends across a broad range of drug classes and indications, like CAR-T therapy in solid tumors.